Ovarian cancers represent the most lethal group of gynaecological malignancies, as most patients are diagnosed at an advanced stage.1 Despite advancements in chemotherapy and surgery, patients’ prognoses have not significantly improved over the last few decades.2 Bevacizumab, an anti-VEGF antibody and an anti-angiogenic agent, was approved as the first effective molecular therapeutic against ovarian cancer. Here, VEGFA is linked to ovarian carcinoma.